Advances in Cancer Research最新文献_第10页

Circ-ADAM9: a novel biomarker in human cancers Circ-ADAM9:一种新的人类癌症生物标志物

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522001

Melika Amelimojarad, Mandana AmeliMojarad

引用次数: 3

Primary mucinous carcinoma of the thyroid:case report and review of the literature 原发性甲状腺粘液癌:病例报告及文献复习

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522023

Neng-Liang Zhang, Jian-hua Wang, W. Cheng, Zheng Li, Jie-qing Tang, Tao Wang, Yi Chen

引用次数: 0

Predictive factors for the post embolization fever after transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a single center study in China 肝癌患者经导管动脉化疗栓塞后发热的预测因素:中国单中心研究

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522021

Dan Tian, Tingting Chen, Qing Xu, Xiaoyu Li, Qian-zhou Lv

引用次数: 1

Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance. 肝癌相关成纤维细胞在肝内胆管癌进展和治疗耐药中的作用。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.01.009

Aashreya Ravichandra, Sonakshi Bhattacharjee, Silvia Affò

{"title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.","authors":"Aashreya Ravichandra, Sonakshi Bhattacharjee, Silvia Affò","doi":"10.1016/bs.acr.2022.01.009","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.01.009","url":null,"abstract":"Cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cell type in the tumor microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA), where they are actively involved in cancer progression through a complex network of interactions with other stromal cells. The majority of the studies investigating CAFs in iCCA have focused their attention on CAF tumor-promoting roles, remarking their potential as therapeutic targets. However, indiscriminate targeting of CAFs in other desmoplastic tumors has ended in failure with no effects or even accelerated cancer progression and reduced survival, indicating the urgent need to better understand the nuances and functions of CAFs to avoid deleterious effects. Indeed, recent single cell RNA sequencing studies have shown that heterogeneous CAF subpopulations coexist in the same tumor, some promoting- and other restricting- tumor growth. Moreover, recent studies have shown that in iCCA, diverse CAF subtypes interact differently with the cells of the TME, suggesting that CAFs may dynamically change their phenotypes during tumor progression, a field that remains uninvestigated. The characterization of heterogenous CAF subpopulations and their functionality, will provide a feasible and safer approach to facilitate the development of new therapeutic approaches aimed at targeting CAFs and their interactions with other stromal cells in the TME rather than solely tumor cells in iCCA. Here, we discuss the origin of CAFs, as well as their heterogeneity, plasticity, mechanisms and targeting strategies to provide a brief snapshot of the current knowledge in iCCA.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"201-226"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10362332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Understanding the genetic basis for cholangiocarcinoma. 了解胆管癌的遗传基础。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.03.004

Mikayla A Schmidt, Lewis R Roberts

{"title":"Understanding the genetic basis for cholangiocarcinoma.","authors":"Mikayla A Schmidt, Lewis R Roberts","doi":"10.1016/bs.acr.2022.03.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.03.004","url":null,"abstract":"Cholangiocarcinoma is associated with several different risk factors, many of which have known genetic associations. Advances in our understanding of the human genome have translated to the development of gene specific and whole genome assays for identifying gene variants and other alterations associated with cancer development. An improved understanding of the inherited genetic variants associated with risk of cholangiocarcinoma has the potential to improve our understanding of the basic biology of cholangiocarcinoma, enhance the performance of risk stratification models for identifying individuals at highest risk for cholangiocarcinoma, and identifying genetic variants associated with predisposition to cholangiocarcinoma in families with multiple affected individuals. It is increasingly recognized that major cancer-causing mutations or other gene alterations associated with familial risk of multiple cancers can also occur as germline events in individuals with apparently sporadically occurring cancer. In this chapter we review the major risk factors for cholangiocarcinoma as well as known gene variants associated with these risk factors, gene variants that have been associated with cholangiocarcinoma as the result of interrogation of candidate genes known to be associated with putative cancer causing pathways in cholangiocarcinoma, as well as the prevalence of major cancer causing genetic aberrations shown to be inherited in the germline of patients with sporadically developed cholangiocarcinoma. There has not yet been any large-scale genome wide association study of cholangiocarcinoma, and the results from such a study are eagerly anticipated.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"137-165"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers. 原发性肝癌肿瘤间和肿瘤内异质性的原因和功能复杂性。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.01.006

Subreen A Khatib, Xin Wei Wang

{"title":"Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers.","authors":"Subreen A Khatib, Xin Wei Wang","doi":"10.1016/bs.acr.2022.01.006","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.01.006","url":null,"abstract":"Tumor heterogeneity is a major feature of primary liver cancers. Defined as the unique genotypic and phenotypic differences of cancer cells within a single tumor (intratumor) or amongst different patients (intertumor), tumor heterogeneity has consistently been linked to worse clinical outcomes in most, if not all, solid tumor types. In particular, liver cancer heterogeneity has been associated with altered immune infiltration, resistance to therapeutics, and worse overall patient survival. Current advancements in single-cell omic technologies have allowed for a deeper understanding and appreciation of the intricate composition and relationships between individual cells within a tumor. These observations have led to the discovery of new cell types in liver cancer, potential new mechanisms of therapy resistance and tumor progression, and new insights into the evolutionary patterns of liver cancer. To better understand the tumor biology of liver cancers and their heterogeneous features, we will begin this chapter on a brief background of liver cancer and then discuss the various etiologies of this disease and how each one can contribute to diverse genomic, transcriptomic, proteomic, and spatial architecture observations. Next, we will go into the specific causes and implications of tumor heterogeneity and end with how understanding the spatial architecture of liver tumors can provide us with new insights and ideas for tumor diversity and therapeutic development.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"75-102"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of genetic heterogeneity in hepatocellular cancer. 肝细胞癌遗传异质性的影响。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-03-07 DOI: 10.1016/bs.acr.2022.01.007

Akanksha Suresh, Renumathy Dhanasekaran

{"title":"Implications of genetic heterogeneity in hepatocellular cancer.","authors":"Akanksha Suresh, Renumathy Dhanasekaran","doi":"10.1016/bs.acr.2022.01.007","DOIUrl":"10.1016/bs.acr.2022.01.007","url":null,"abstract":"Hepatocellular carcinoma (HCC) exhibits a remarkable degree of heterogeneity, not only at an inter-patient level but also between and within tumors in the same patient. The advent of next-generation sequencing (NGS)-based technologies has allowed the creation of high-resolution atlases of HCC. This review outlines recent findings from genomic, epigenomic, transcriptomic, and proteomic sequencing that have yielded valuable insights into the spatial and temporal heterogeneity of HCC. The high heterogeneity of HCC has both clinical and therapeutic implications. The challenges in prospectively validating molecular classifications for HCC either for prognostication or for prediction of therapeutic response are partly due to the immense heterogeneity in HCC. Moreover, the heterogeneity of HCC tumors combined with the lack of commonly mutated, druggable targets severely limits treatment options for HCC. Recently, immune checkpoint inhibitors and combination therapies have shown promise for advanced HCC, while T cell therapies and vaccines are currently being investigated. Yet, immunotherapies show benefit only in a limited subset of patients, making it imperative to decipher tumor heterogeneity in HCC in order to enable optimal patient selection. This review summarizes the cutting-edge research on heterogeneity in HCC and explores the implications of heterogeneity on stratifying patients and developing biomarkers and therapies for HCC.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"103-135"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321863/pdf/nihms-1903016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9755327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. 肝内胆管癌的发病机制和治疗中的 YAP1 激活和 Hippo 通路信号传导。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-03-09 DOI: 10.1016/bs.acr.2022.02.003

Sungjin Ko, Minwook Kim, Laura Molina, Alphonse E Sirica, Satdarshan P Monga

{"title":"YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.","authors":"Sungjin Ko, Minwook Kim, Laura Molina, Alphonse E Sirica, Satdarshan P Monga","doi":"10.1016/bs.acr.2022.02.003","DOIUrl":"10.1016/bs.acr.2022.02.003","url":null,"abstract":"Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer, is a highly lethal epithelial cell malignancy exhibiting features of cholangiocyte differentiation. iCCAs can potentially develop from multiple cell types of origin within liver, including immature or mature cholangiocytes, hepatic stem cells/progenitor cells, and from transdifferentiation of hepatocytes. Understanding the molecular mechanisms and genetic drivers that diversely drive specific cell lineage pathways leading to iCCA has important biological and clinical implications. In this context, activation of the YAP1-TEAD dependent transcription, driven by Hippo-dependent or -independent diverse mechanisms that lead to the stabilization of YAP1 is crucially important to biliary fate commitment in hepatobiliary cancer. In preclinical models, YAP1 activation in hepatocytes or cholangiocytes is sufficient to drive their malignant transformation into iCCA. Moreover, nuclear YAP1/TAZ is highly prevalent in human iCCA irrespective of the varied etiology, and significantly correlates with poor prognosis in iCCA patients. Based on the ubiquitous expression and diverse physiologic roles for YAP1/TAZ in the liver, recent studies have further revealed distinct functions of active YAP1/TAZ in regulating tumor metabolism, as well as the tumor immune microenvironment. In the current review, we discuss our current understanding of the various roles of the Hippo-YAP1 signaling in iCCA pathogenesis, with a specific focus on the roles played by the Hippo-YAP1 pathway in modulating biliary commitment and oncogenicity, iCCA metabolism, and immune microenvironment. We also discuss the therapeutic potential of targeting the YAP1/TAZ-TEAD transcriptional machinery in iCCA, its current limitations, and what future studies are needed to facilitate clinical translation.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"283-317"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972177/pdf/nihms-1873255.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. 并非所有的RAS突变都是相同的:详细回顾了RAS热点突变的功能多样性。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2021-08-23 DOI: 10.1016/bs.acr.2021.07.004

Rachel A Burge, G Aaron Hobbs

{"title":"Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations.","authors":"Rachel A Burge, G Aaron Hobbs","doi":"10.1016/bs.acr.2021.07.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2021.07.004","url":null,"abstract":"The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Approximately 20% of cancers harbor a RAS mutation, and >150 different missense mutations have been detected. Many of these mutations have mutant-specific biochemical defects that alter nucleotide binding and hydrolysis, effector interactions and cell signaling, prompting renewed efforts in the development of anti-RAS therapies, including the mutation-specific strategies. Previously viewed as undruggable, the recent FDA approval of a KRASG12C-selective inhibitor has offered real promise to the development of allele-specific RAS therapies. A broader understanding of the mutational consequences on RAS function must be developed to exploit additional allele-specific vulnerabilities. Approximately 94% of RAS mutations occur at one of three mutational \"hot spots\" at Gly12, Gly13 and Gln61. Further, the single-nucleotide substitutions represent >99% of these mutations. Within this scope, we discuss the mutational frequencies of RAS isoforms in cancer, mutant-specific effector interactions and biochemical properties. By limiting our analysis to this mutational subset, we simplify the analysis while only excluding a small percentage of total mutations. Combined, these data suggest that the presence or absence of select RAS mutations in human cancers can be linked to their biochemical properties. Continuing to examine the biochemical differences in each RAS-mutant protein will continue to provide additional breakthroughs in allele-specific therapeutic strategies.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"29-61"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39875998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

An overview of chemotoxicity and radiation toxicity in cancer therapy. 癌症治疗中的化学毒性和放射毒性综述。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-04-30 DOI: 10.1016/bs.acr.2022.03.007

Victor Yazbeck, Erin Alesi, Jennifer Myers, Mary Helen Hackney, Laurie Cuttino, David A Gewirtz

{"title":"An overview of chemotoxicity and radiation toxicity in cancer therapy.","authors":"Victor Yazbeck, Erin Alesi, Jennifer Myers, Mary Helen Hackney, Laurie Cuttino, David A Gewirtz","doi":"10.1016/bs.acr.2022.03.007","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.03.007","url":null,"abstract":"While immunotherapy and targeted therapies represent major advances against different types of malignancies, the mainstay of cancer therapy continues to be radiation and surgery for localized disease, and chemotherapy for systemic disease, with the preponderance of chemotherapeutic agents (such as anthracyclines, alkylating agents, and antimetabolites) having been developed decades ago. Combination chemotherapy regimens have changed the natural history of once deadly diseases such as breast and prostate cancer and led to curative regimens in advanced hematological malignancies and testicular cancer. However, while oncologists maintain their focus on disease suppression, and where feasible, disease eradication, obstacles to achieving cure remain, such as tumor dormancy and ultimately disease recurrence, as well as both intrinsic and acquired resistance. In this review, complications of current cancer therapies toward major organs (heart, lung, kidney, gastro-intestinal, neuromuscular, brain, and skin) are emphasized, and efforts to mitigate these complications are described. This is particularly relevant for patients treated with curative intent, where adherence to treatment plan, and avoidance of interruptions in treatment schedule are essential for optimal outcome. Consequently, these patients are treated with an \"aggressive\" approach, with high tolerance for side effects. However, a deeper understanding of normal tissue toxicity resulting from the different cancer therapies remains an area of unmet medical need that will ultimately lead to improved therapeutic index for current and future therapies, planning for treatment adverse effects, and ultimately improvement in patient satisfaction, compliance and outcome.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"1-27"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11